Verve Therapeutics, Inc. clinical trials
Acquired by Eli Lilly and Company, Jul 25, 2025 · source ↗
The registry lists 5 studies whose lead sponsor is Verve Therapeutics, Inc.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 10, 2026.
- 5studies on the registry
- 4open to participants now
Before and after it joined Eli Lilly and Company
- First submitted before Verve Therapeutics, Inc. became part of Eli Lilly and Company
- 4
- First submitted after Verve Therapeutics, Inc. became part of Eli Lilly and Company
- 1
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting1
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseaseNov 10, 2026NCT07839936
All 5 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 22
- 23
- 324
- 25
- 126
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Verve Therapeutics, Inc.5 studies
Something wrong with this grouping? Tell us on the Eli Lilly and Company page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Eli Lilly and Company studies →
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseaseRecruitingNCT07839936Phase 2
Sponsor listed in the registry: Verve Therapeutics, Inc. · First submitted after Verve Therapeutics, Inc. became part of Eli Lilly and Company
- Phase 1b Study of VERVE-201 in Patients With Refractory HyperlipidemiaRecruitingNCT06451770Phase 1
Sponsor listed in the registry: Verve Therapeutics, Inc. · First submitted before Verve Therapeutics, Inc. became part of Eli Lilly and Company
- A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery DiseaseRecruitingNCT06164730Phase 1
Sponsor listed in the registry: Verve Therapeutics, Inc. · First submitted before Verve Therapeutics, Inc. became part of Eli Lilly and Company
- Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular DiseaseEnrolling by invitationNCT06112327
Sponsor listed in the registry: Verve Therapeutics, Inc. · First submitted before Verve Therapeutics, Inc. became part of Eli Lilly and Company
- A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular DiseaseCompletedNCT05398029Phase 1
Sponsor listed in the registry: Verve Therapeutics, Inc. · First submitted before Verve Therapeutics, Inc. became part of Eli Lilly and Company